Document:

EXHIBIT 10.4

                         HEALTH SYSTEMS SOLUTIONS, INC.
                              A Nevada Corporation

                          REGISTRATION RIGHTS AGREEMENT

         THIS REGISTRATION RIGHTS AGREEMENT, dated as of April 30, 2003 (the
"Agreement"), is entered into by and among Health Systems Solutions, Inc., a
Nevada corporation (the "Company"), and the holders (the "Investors") of the
Company's capital stock set forth on the signature page hereof. Capitalized
terms not defined herein shall have the meanings ascribed to them in the
Securities Purchase Agreement (as hereinafter defined).

         WHEREAS, simultaneously with the execution and delivery of this
Agreement, the Investors are agreeing to purchase from the Company, pursuant to
the Securities Purchase Agreement dated as of April 30, 2003 entered into by and
between the Company and Stanford Venture Capital Holdings, Inc., a Delaware
corporation (the "Securities Purchase Agreement") 2,500,000 shares of the
Company's Series B Preferred Stock; and

         WHEREAS, the Company desires to grant to the Investors the registration
rights set forth herein with respect to the shares of Common Stock issuable upon
conversion of the Series B Preferred Stock (the "Conversion Shares"), and the
shares of Common Stock issued as a dividend or other distribution with respect
to the Conversion Shares (the "Distribution Shares") (all the shares of the
Series B Preferred Stock, the Conversion Shares and the Distribution Shares,
collectively and interchangeably, are referred to herein as the "Securities").

         NOW, THEREFORE, the parties hereto mutually agree as follows:

         1. CERTAIN DEFINITIONS

         As used herein the term "Registrable Security" means the Conversion
Shares and the Distribution Shares, until (i) the Registration Statement (as
defined below) has been declared effective by the Securities and Exchange
Commission (the "Commission"), and all Securities have been disposed of pursuant
to the Registration Statement, (ii) all Securities have been sold under
circumstances under which all of the applicable conditions of Rule 144 ("Rule
144") (or any similar provision then in force) under the Securities Act of 1933,
as amended (the "Securities Act") are met, or (iii) such time as, in the opinion
of counsel to the Company reasonably satisfactory to the Investors and upon
delivery to the Investors of such executed opinion, all Securities may be sold
without any time, volume or manner limitations pursuant to Rule 144 (or any
similar provision then in effect). In the event of any merger, reorganization,
consolidation, recapitalization or other change in corporate structure affecting
the Common Stock, such adjustment shall be deemed to be made in the definition
of "Registrable Security" as is appropriate in order to prevent any dilution or
enlargement of the rights granted pursuant to this Agreement. As used herein the
term "Holder" means any Person owning or having the right to acquire Registrable
Securities or any assignee thereof in accordance with Section 10 hereof. As used
herein "Trading Day" shall mean any business day on which the market on which
the Common Stock trades is open for business.

<PAGE>
         2. RESTRICTIONS ON TRANSFER

         Each of the Investors acknowledges and understands that prior to the
registration of the Securities as provided herein, the Securities are
"restricted securities" as defined in Rule 144. Each of the Investors
understands that no disposition or transfer of the Securities may be made by any
of the Investors in the absence of (i) an opinion of counsel to such Investor,
in form and substance reasonably satisfactory to the Company, that such transfer
may be made without registration under the Securities Act or (ii) such
registration.

         3. COMPLIANCE WITH REPORTING REQUIREMENTS

         With a view to making available to the Investors the benefits of Rule
144 or any other similar rule or regulation of the Commission that may at any
time permit the holders of the Securities to sell securities of the Company to
the public pursuant to Rule 144, the Company agrees to:

            (a) comply with the provisions of paragraph (c)(1) of Rule 144;

            (b) file with the Commission in a timely manner all reports and
other documents required to be filed with the Commission pursuant to Section 13
or 15(d) under the Securities Exchange Act of 1934 (the "Exchange Act") by
companies subject to either of such sections, irrespective of whether the
Company is then subject to such reporting requirements; and

            (c) Upon request by any Holder or the Company's transfer agent, the
Company shall provide an opinion of counsel, which opinion shall be reasonably
acceptable to the Holder and/or the Company's transfer agent, that the such
Holder has complied with the applicable conditions of Rule 144 (or any similar
provision then in force).

         4. REGISTRATION RIGHTS WITH RESPECT TO THE REGISTRABLE SECURITIES

            (a) The Company agrees that it will prepare and file with the
Commission, (i) on or before December 31, 2003, a registration statement (on
Form S-1 or SB-2, or other appropriate registration statement form) under the
Securities Act (the "Registration Statement"), and (ii) if at least 20% of the
Registrable Securities covered under the Registration Statement filed under (i)
remain unsold during the effective period of such Registration Statement, then
within 20 days following receipt of a written notice from the holders
representing a majority of such unsold Registrable Securities, another
Registration Statement so as to permit a resale of the Securities under the
Securities Act by the Holders as selling stockholders and not as underwriters.

         The Company shall use diligent best efforts to cause the Registration
Statement to become effective as soon as practical following the filing of the
Registration Statement. The number of shares designated in the Registration
Statement to be registered shall include 150% of the Conversion Shares and shall
include appropriate language regarding reliance upon Rule 416 to the extent
permitted by the Commission. The Company will notify the Holders and its
transfer agent of the effectiveness of the Registration Statement within one
Trading Day of such event.

                                        2
<PAGE>
            (b) The Company will maintain the Registration Statement or
post-effective amendment filed under this Section 4 effective under the
Securities Act until the earlier of (i) the date that none of the Registrable
Securities covered by such Registration Statement are or may become issued and
outstanding, (ii) the date that all of the Registrable Securities have been sold
pursuant to such Registration Statement, (iii) the date all the Holders receive
an opinion of counsel to the Company, which counsel shall be reasonably
acceptable to the Holders, that the Registrable Securities may be sold under the
provisions of Rule 144 without limitation as to volume, (iv) all Registrable
Securities have been otherwise transferred to persons who may trade such shares
without restriction under the Securities Act, and the Company has delivered a
new certificate or other evidence of ownership for such securities not bearing a
restrictive legend, or (v) two years from the Effective Date.

            (c) All fees, disbursements and out-of-pocket expenses and costs
incurred by the Company in connection with the preparation and filing of the
Registration Statement under this Section 4 and in complying with applicable
securities and blue sky laws (including, without limitation, all attorneys' fees
of the Company) shall be borne by the Company. The Company shall also reimburse
the fees and expenses of counsel to the Holders incurred in connection with such
counsel's review of the Registration Statement and advice concerning the
Registration Statement and its filing subject to a cap of $15,000. The Holders
shall bear the cost of underwriting and/or brokerage discounts, fees and
commissions, if any, applicable to the Registrable Securities being registered.
The Holders and their counsel shall have a reasonable period, not to exceed 15
Trading Days, to review the proposed Registration Statement or any amendment
thereto, prior to filing with the Commission, and the Company shall provide the
Holders with copies of any comment letters received from the Commission with
respect thereto within two Trading Days of receipt thereof. The Company shall
qualify any of the Registrable Securities for sale in such states as the Holders
reasonably designate and shall furnish indemnification in the manner provided in
Section 7 hereof. However, the Company shall not be required to qualify in any
state which will require an escrow or other restriction relating to the Company
and/or the Holders, or which will require the Company to qualify to do business
in such state or require the Company to file therein any general consent to
service of process. The Company at its expense will supply each of the Investors
with copies of the applicable Registration Statement and the prospectus included
therein and other related documents in such quantities as may be reasonably
requested by any of the Investors.

            (d) The Company shall not be required by this Section 4 to include
the Registrable Securities in any Registration Statement which is to be filed
if, in the opinion of counsel for both the Holders and the Company (or, should
they not agree, in the opinion of another counsel experienced in securities law
matters acceptable to counsel for the Holders and the Company) the proposed
offering or other transfer as to which such registration is requested is exempt
from applicable federal and state securities laws and would result in all
purchasers or transferees obtaining securities which are not "restricted
securities," as defined in Rule 144.

            (e) In the event that (i) the Registration Statement is not filed by
the Company in a timely manner as set forth in Section 4(a); or (ii) such
Registration Statement is not maintained as effective by the Company for the
period set forth in Section 4(b) above (each a "Registration Default"), then the

                                       3
<PAGE>
Company will issue to each of the Holders as of the first day of such
Registration Default and for every consecutive month in which such Registration
Default is occurring, as liquidated damages, and not as a penalty, five year
warrants exercisable at a price per share equal to the latest conversion price
of the Series B Preferred Stock to purchase one (1) share of the Common Stock
("Default Warrants") for each share of Series B Preferred Stock issued to the
Holders pursuant to the Securities Purchase Agreement until such corresponding
Registration Default no longer exists ("Liquidated Damages"); provided, however,
that the issuance of such Default Warrants shall not relieve the Company from
its obligations to register the Registrable Securities pursuant to this Section.

         If the Company does not issue the Default Warrants to the Holders as
set forth above, the Company will pay any Holder's reasonable costs of any
action in a court of law to cause compliance with this Section 4(e), including
reasonable attorneys' fees, in addition to the Default Warrants. The
registration of the Registrable Securities pursuant to this Section shall not
affect or limit a Holder's other rights or remedies as set forth in this
Agreement.

            (f) The Company shall be precluded from including in any
Registration Statement which it is required to file pursuant to this Section 4
any other securities apart from the Registrable Securities, without the prior
written consent of the Holders.

            (g) If, at any time any Registrable Securities are not at the time
covered by any effective Registration Statement, the Company shall determine to
register under the Securities Act (including pursuant to a demand of any
stockholder of the Company exercising registration rights) any of its shares of
the Common Stock (other than in connection with a merger or other business
combination transaction that has been consented to in writing by holders of the
Series B Preferred Stock, or pursuant to Form S-8 when such filing has been
consented to in writing by holders of the Series B Preferred Stock), it shall
send to each Holder written notice of such determination and, if within 20 days
after receipt of such notice, such Holder shall so request in writing, the
Company shall its best efforts to include in such registration statement all or
any part of the Registrable Securities that such Holder requests to be
registered. Notwithstanding the foregoing, if, in connection with any offering
involving an underwriting of the Common Stock to by issued by the Company, the
managing underwriter shall impose a limitation on the number of shares of the
Common Stock included in any such registration statement because, in such
underwriter's judgment, such limitation is necessary based on market conditions:
(a) if the registration statement is for a public offering of common stock on a
"firm commitment" basis with gross proceeds to the Company of at least
$15,000,000 (a "Qualified Public Offering"), the Company may exclude, to the
extent so advised by the underwriters, the Registrable Securities from the
underwriting; provided, however, that if the underwriters do not entirely
exclude the Registrable Securities from such Qualified Public Offering, the
Company shall be obligated to include in such registration statement, with
respect to the requesting Holder, only an amount of Registrable Securities equal
to the product of (i) the number of Registrable Securities that remain available
for registration after the underwriter's cutback and (ii) such Holder's
percentage of ownership of all the Registrable Securities then outstanding (on
an as-converted basis) (the "Registrable Percentage"); and (b) if the
registration statement is not for a Qualified Public Offering, the Company shall
be obligated to include in such registration statement, with respect to the
requesting Holder, only an amount of Registrable Securities equal to the product
of (i) the number of Registrable Securities that remain available for
registration after the underwriter's cutback and (ii) such Holder's Registrable
Percentage; provided, however, that the aggregate value of the Registrable

                                       4
<PAGE>
Securities to be included in such registration may not be so reduced to less
than 30% of the total value of all securities included in such registration. If
any Holder disapproves of the terms of any underwriting referred to in this
paragraph, it may elect to withdraw therefrom by written notice to the Company
and the underwriter. No incidental right under this paragraph shall be construed
to limit any registration required under the other provisions of this Agreement.

         5. COOPERATION WITH COMPANY

         Each Holder will cooperate with the Company in all respects in
connection with this Agreement, including timely supplying all information
reasonably requested by the Company (which shall include all information
regarding such Holder and proposed manner of sale of the Registrable Securities
required to be disclosed in any Registration Statement) and executing and
returning all documents reasonably requested in connection with the registration
and sale of the Registrable Securities and entering into and performing its
obligations under any underwriting agreement, if the offering is an underwritten
offering, in usual and customary form, with the managing underwriter or
underwriters of such underwritten offering. Nothing in this Agreement shall
obligate any Holder to consent to be named as an underwriter in any Registration
Statement. The obligation of the Company to register the Registrable Securities
shall be absolute and unconditional as to those Registrable Securities which the
Commission will permit to be registered without naming any Holder as
underwriters. Any delay or delays caused by a Holder by failure to cooperate as
required hereunder shall not constitute a Registration Default as to such
Holder.

         6. REGISTRATION PROCEDURES

         If and whenever the Company is required by any of the provisions of
this Agreement to effect the registration of any of the Registrable Securities
under the Securities Act, the Company shall (except as otherwise provided in
this Agreement), as expeditiously as possible, subject to the Holders'
assistance and cooperation as reasonably required with respect to each
Registration Statement:

            (a) (i) prepare and file with the Commission such amendments and
supplements to the Registration Statement and the prospectus used in connection
therewith as may be necessary to keep such Registration Statement effective and
to comply with the provisions of the Securities Act with respect to the sale or
other disposition of all Registrable Securities covered by such Registration
Statement whenever any of the Holder shall desire to sell or otherwise dispose
of the same (including prospectus supplements with respect to the sales of
Registrable Securities from time to time in connection with a registration
statement pursuant to Rule 415 promulgated under the Securities Act) and (ii)
take all lawful action such that each of (A) the Registration Statement and any
amendment thereto does not, when it becomes effective, contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading and (B) the prospectus
forming part of the Registration Statement, and any amendment or supplement
thereto, does not at any time during the Registration Period include an untrue
statement of a material fact or omit to state a material fact required to be

                                       5
<PAGE>
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading;

            (b) (i) prior to the filing with the Commission of any Registration
Statement (including any amendments thereto) and the distribution or delivery of
any prospectus (including any supplements thereto), provide draft copies thereof
to the Holders as required by Section 4(c) and reflect in such documents all
such comments as the Holders (and their counsel) reasonably may propose; (ii)
furnish to each of the Holders such numbers of copies of a prospectus including
a preliminary prospectus or any amendment or supplement to any prospectus, as
applicable, in conformity with the requirements of the Securities Act, and such
other documents, as any of the Holders may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Securities
owned by such Holder; and (iii) provide to the Holders copies of any comments
and communications from the Commission relating to the Registration Statement,
if lawful to do so;

            (c) register and qualify the Registrable Securities covered by the
Registration Statement under such other securities or blue sky laws of such
jurisdictions as any of the Holders shall reasonably request (subject to the
limitations set forth in Section 4(c) above), and do any and all other acts and
things which may be necessary or advisable to enable such Holder to consummate
the public sale or other disposition in such jurisdiction of the Registrable
Securities owned by such Holder;

            (d) list such Registrable Securities on the markets where the Common
Stock of the Company is listed as of the effective date of the Registration
Statement, if the listing of such Registrable Securities is then permitted under
the rules of such markets;

            (e) notify the Holders at any time when a prospectus relating
thereto covered by the Registration Statement is required to be delivered under
the Securities Act, of the happening of any event of which it has knowledge as a
result of which the prospectus included in the Registration Statement, as then
in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing, and the
Company shall prepare and file a curative amendment under Section 6(a) as
quickly as reasonably possible and during such period, the Holders shall not
make any sales of Registrable Securities pursuant to the Registration Statement;

            (f) after becoming aware of such event, notify each of the Holders
who holds Registrable Securities being sold (or, in the event of an underwritten
offering, the managing underwriters) of the issuance by the Commission of any
stop order or other suspension of the effectiveness of the Registration
Statement at the earliest possible time and take all lawful action to effect the
withdrawal, rescission or removal of such stop order or other suspension;

            (g) cooperate with the Holders to facilitate the timely preparation
and delivery of certificates for the Registrable Securities to be offered
pursuant to the Registration Statement and enable such certificates for the
Registrable Securities to be in such denominations or amounts, as the case may
be, as any of the Holders reasonably may request and registered in such names as
any of the Holders may request; and, within three Trading Days after a

                                       6
<PAGE>
Registration Statement which includes Registrable Securities is declared
effective by the Commission, deliver and cause legal counsel selected by the
Company to deliver to the transfer agent for the Registrable Securities (with
copies to the Holders) an appropriate instruction and, to the extent necessary,
an opinion of such counsel;

            (h) take all such other lawful actions reasonably necessary to
expedite and facilitate the disposition by the Holders of their Registrable
Securities in accordance with the intended methods therefor provided in the
prospectus which are customary for issuers to perform under the circumstances;

            (i) in the event of an underwritten offering, promptly include or
incorporate in a prospectus supplement or post-effective amendment to the
Registration Statement such information as the managers reasonably agree should
be included therein and to which the Company does not reasonably object and make
all required filings of such prospectus supplement or post-effective amendment
as soon as practicable after it is notified of the matters to be included or
incorporated in such prospectus supplement or post-effective amendment; and

            (j) maintain a transfer agent and registrar for the Common Stock.

         7. INDEMNIFICATION

            (a) To the maximum extent permitted by law, the Company agrees to
indemnify and hold harmless each of the Holders, each person, if any, who
controls any of the Holders within the meaning of the Securities Act, and each
director, officer, shareholder, employee, agent, representative, accountant or
attorney of the foregoing (each of such indemnified parties, a "Distributing
Investor") against any losses, claims, damages or liabilities, joint or several
(which shall, for all purposes of this Agreement, include, but not be limited
to, all reasonable costs of defense and investigation and all reasonable
attorneys' fees and expenses), to which the Distributing Investor may become
subject, under the Securities Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any untrue statement or alleged untrue statement of any material fact
contained in any Registration Statement, or any related final prospectus or
amendment or supplement thereto, or arise out of or are based upon the omission
or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading; provided,
however, that the Company will not be liable in any such case to the extent, and
only to the extent, that any such loss, claim, damage or liability arises out of
or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in such Registration Statement, preliminary prospectus,
final prospectus or amendment or supplement thereto in reliance upon, and in
conformity with, written information furnished to the Company by the
Distributing Investor, its counsel, or affiliates, specifically for use in the
preparation thereof or (ii) by such Distributing Investor's failure to deliver
to the purchaser a copy of the most recent prospectus (including any amendments
or supplements thereto). This indemnity agreement will be in addition to any
liability which the Company may otherwise have.

            (b) To the maximum extent permitted by law, each Distributing
Investor agrees that it will indemnify and hold harmless the Company, and each
officer and director of the Company or person, if any, who controls the Company

                                       7
<PAGE>
within the meaning of the Securities Act, against any losses, claims, damages or
liabilities (which shall, for all purposes of this Agreement, include, but not
be limited to, all reasonable costs of defense and investigation and all
reasonable attorneys' fees and expenses) to which the Company or any such
officer, director or controlling person may become subject under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon any untrue statement
or alleged untrue statement of any material fact contained in any Registration
Statement, or any related final prospectus or amendment or supplement thereto,
or arise out of or are based upon the omission or the alleged omission to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, but in each case only to the extent that such
untrue statement or alleged untrue statement or omission or alleged omission was
made in such Registration Statement, final prospectus or amendment or supplement
thereto in reliance upon, and in conformity with, written information furnished
to the Company by such Distributing Investor, its counsel or affiliates,
specifically for use in the preparation thereof. This indemnity agreement will
be in addition to any liability which the Distributing Investor may otherwise
have under this Agreement. Notwithstanding anything to the contrary herein, the
Distributing Investor shall be liable under this Section 7(b) for only that
amount as does not exceed the net proceeds to such Distributing Investor as a
result of the sale of Registrable Securities pursuant to the Registration
Statement.

            (c) Promptly after receipt by an indemnified party under this
Section 7 of notice of the commencement of any action against such indemnified
party, such indemnified party will, if a claim in respect thereof is to be made
against the indemnifying party under this Section 7, notify the indemnifying
party in writing of the commencement thereof; but the omission so to notify the
indemnifying party will not relieve the indemnifying party from any liability
which it may have to any indemnified party except to the extent the failure of
the indemnified party to provide such written notification actually prejudices
the ability of the indemnifying party to defend such action. In case any such
action is brought against any indemnified party, and it notifies the
indemnifying party of the commencement thereof, the indemnifying party will be
entitled to participate in, and, to the extent that it may wish, jointly with
any other indemnifying party similarly notified, assume the defense thereof,
subject to the provisions herein stated and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party will not be liable to such indemnified party
under this Section 7 for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof other than
reasonable costs of investigation, unless the indemnifying party shall not
pursue the action to its final conclusion. The indemnified parties shall have
the right to employ one or more separate counsel in any such action and to
participate in the defense thereof, but the fees and expenses of such counsel
shall not be at the expense of the indemnifying party if the indemnifying party
has assumed the defense of the action with counsel reasonably satisfactory to
the indemnified party unless (i) the employment of such counsel has been
specifically authorized in writing by the indemnifying party, or (ii) the named
parties to any such action (including any interpleaded parties) include both the
indemnified party and the indemnifying party and the indemnified party shall
have been advised by its counsel that there may be one or more legal defenses
available to the indemnifying party different from or in conflict with any legal
defenses which may be available to the indemnified party or any other
indemnified party (in which case the indemnifying party shall not have the right
to assume the defense of such action on behalf of such indemnified party, it
being understood, however, that the indemnifying party shall, in connection with
any one such action or separate but substantially similar or related actions in

                                       8
<PAGE>
the same jurisdiction arising out of the same general allegations or
circumstances, be liable only for the reasonable fees and expenses of one
separate firm of attorneys for the indemnified party, which firm shall be
designated in writing by the indemnified party). No settlement of any action
against an indemnified party shall be made without the prior written consent of
the indemnified party, which consent shall not be unreasonably withheld so long
as such settlement includes a full release of claims against the indemnified
party.

         All fees and expenses of the indemnified party (including reasonable
costs of defense and investigation in a manner not inconsistent with this
Section and all reasonable attorneys' fees and expenses) shall be paid to the
indemnified party, as incurred, within 10 Trading Days of written notice thereof
to the indemnifying party; provided, that the indemnifying party may require
such indemnified party to undertake to reimburse all such fees and expenses to
the extent it is finally judicially determined that such indemnified party is
not entitled to indemnification hereunder.

         8. CONTRIBUTION

         In order to provide for just and equitable contribution under the
Securities Act in any case in which (i) the indemnified party makes a claim for
indemnification pursuant to Section 7 hereof but is judicially determined (by
the entry of a final judgment or decree by a court of competent jurisdiction and
the expiration of time to appeal or the denial of the last right of appeal) that
such indemnification may not be enforced in such case notwithstanding the fact
that the express provisions of Section 7 hereof provide for indemnification in
such case, or (ii) contribution under the Securities Act may be required on the
part of any indemnified party, then the Company and the applicable Distributing
Investor shall contribute to the aggregate losses, claims, damages or
liabilities to which they may be subject (which shall, for all purposes of this
Agreement, include, but not be limited to, all reasonable costs of defense and
investigation and all reasonable attorneys' fees and expenses), in either such
case (after contribution from others) on the basis of relative fault as well as
any other relevant equitable considerations. The relative fault shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company on the one hand
or the applicable Distributing Investor on the other hand, and the parties'
relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Company and the Distributing Investor
agree that it would not be just and equitable if contribution pursuant to this
Section 8 were determined by pro rata allocation or by any other method of
allocation which does not take account of the equitable considerations referred
to in this Section 8. The amount paid or payable by an indemnified party as a
result of the losses, claims, damages or liabilities (or actions in respect
thereof) referred to above in this Section 8 shall be deemed to include any
legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or claim. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.

         Notwithstanding any other provision of this Section 8, in no event
shall (i) any of the Distributing Investors be required to undertake liability
to any person under this Section 8 for any amounts in excess of the dollar
amount of the proceeds received by such Distributing Investor from the sale of
such Distributing Investor's Registrable Securities (after deducting any fees,

                                       9
<PAGE>
discounts and commissions applicable thereto) pursuant to any Registration
Statement under which such Registrable Securities are registered under the
Securities Act and (ii) any underwriter be required to undertake liability to
any person hereunder for any amounts in excess of the aggregate discount,
commission or other compensation payable to such underwriter with respect to the
Registrable Securities underwritten by it and distributed pursuant to such
Registration Statement.

         9. NOTICES

         Any notice required or permitted hereunder shall be given in writing
(unless otherwise specified herein) and shall be effective upon personal
delivery, via facsimile (upon receipt of confirmation of error-free transmission
and mailing a copy of such confirmation, postage prepaid by certified mail,
return receipt requested) or two business days following deposit of such notice
with an internationally recognized courier service, with postage prepaid and
addressed to each of the other parties thereunto entitled at the following
addresses, or at such other addresses as a party may designate by five days
advance written notice to each of the other parties hereto.

         Company:                            Health Systems Solutions, Inc.
                                             200 South Hoover Boulevard
                                             Building 205
                                             Tampa, Florida 33609
                                             Attention: President
                                             Tel: 813-282-3303
                                             Facsimile: 813-282-8907

         with a copy to:                     Adorno & Yoss, P.A.
                                             2601 S. Bayshore Drive, Suite 1600
                                             Miami, Florida 33133
                                             Attention: Seth P. Joseph, Esq.
                                             Tel: 305-860-7363
                                             Facsimile: 305-858-4777

         Investors:                          At the address and facsimile set
                                             forth on the signature page hereof

         10. ASSIGNMENT

         The registration rights granted to any Holder under this Agreement may
be transferred or assigned provided the transferee is bound by the terms of this
Agreement and the Company is given written notice of such transfer or
assignment.

         11. ADDITIONAL COVENANTS OF THE COMPANY

         For so long as it shall be required to maintain the effectiveness of
the Registration Statement, it shall file all reports and information required

                                       10
<PAGE>
to be filed by it with the Commission in a timely manner and take all such other
action so as to maintain such eligibility for the use of the applicable form.

         12. CONFLICTING AGREEMENTS

         The Company shall not enter into any agreement with respect to its
securities that is inconsistent with the rights granted to the Holders in this
Agreement or otherwise prevents the Company from complying with all of its
obligations hereunder.

         13. GOVERNING LAW; JURISDICTION

         This Agreement shall be governed by and interpreted in accordance with
the laws of the State of Florida, without regard to its principles of conflict
of laws. Any action or proceeding seeking to enforce any provision of, or based
on any right arising out of, this Agreement may be brought against any party in
the federal courts of Florida or the state courts of the State of Florida, and
each of the parties consents to the jurisdiction of such courts and hereby
waives, to the maximum extent permitted by law, any objection, including any
objections based on forum non conveniens, to the bringing of any such proceeding
in such jurisdictions.

         14. MISCELLANEOUS

            (a) Entire Agreement. This Agreement supersedes all prior agreements
and understandings among the parties hereto with respect to the subject matter
hereof. This Agreement, together with the other Primary Documents, including any
certificate, schedule, exhibit or other document delivered pursuant to their
terms, constitutes the entire agreement among the parties hereto with respect to
the subject matters hereof and thereof, and supersedes all prior agreements and
understandings, whether written or oral, among the parties with respect to such
subject matters.

            (b) Amendments. This Agreement may not be amended except by an
instrument in writing signed by the party to be charged with enforcement.

            (c) Waiver. No waiver of any provision of this Agreement shall be
deemed a waiver of any other provisions or shall a waiver of the performance of
a provision in one or more instances be deemed a waiver of future performance
thereof.

            (d) Construction. This Agreement and each of the Primary Documents
have been entered into freely by each of the parties, following consultation
with their respective counsel, and shall be interpreted fairly in accordance
with its respective terms, without any construction in favor of or against
either party.

            (e) Binding Effect of Agreement. This Agreement shall inure to the
benefit of, and be binding upon the successors and assigns of each of the
parties hereto, including any transferees of the Securities.

            (f) Severability. If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or

                                       11
<PAGE>
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement or the validity or unenforceability of this
Agreement in any other jurisdiction.

            (g) Attorneys' Fees. If any action should arise between the parties
hereto to enforce or interpret the provisions of this Agreement, the prevailing
party in such action shall be reimbursed for all reasonable expenses incurred in
connection with such action, including reasonable attorneys' fees.

            (h) Headings. The headings of this Agreement are for convenience of
reference only and shall not form part of, or affect the interpretation of this
Agreement.

            (i) Counterparts. This Agreement may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, when
taken together, will be deemed to constitute one and the same agreement.

                         [SIGNATURES ON FOLLOWING PAGE]

                                       12
<PAGE>
         IN WITNESS WHEREOF, the parties hereto have caused this Registration
Rights Agreement to be duly executed, on this 30th day of April, 2003.

                                         HEALTH SYSTEMS SOLUTIONS, INC.

                                         By: /S/ B.M. MILVAIN
                                            -----------------
                                            Name: B.M. MILVAIN
                                                  ------------
                                            Title: PRESIDENT

                                         STANFORD VENTURE CAPITAL HOLDINGS, INC.

                                         By: /S/JAMES M. DAVIS
                                            ------------------
                                            Name: JAMES M. DAVIS
                                                 ---------------
                                            Title: PRESIDENT

                                         6075 Poplar Avenue
                                         Memphis, TN 38119
                                         Attn: James M. Davis, President

                                       13Exhibit
10.29

 

NEORX CORPORATION

CHANGE OF CONTROL
AGREEMENT (CEO/COO)

 

THIS CHANGE OF CONTROL AGREEMENT (CEO/COO) (this “Agreement”), dated as
of February 12, 2003, is entered into by and between NEORX CORPORATION, a
Washington corporation (as supplemented by Section 13, the “Company”), and DOUG
B. GIVEN, M.D., Ph. D. (the “Executive”).

 

The Board of Directors of the Company (the “Board”) has determined that it is in the best interests
of the Company and its shareholders to ensure that the Company will have the
continued dedication of the Executive, notwithstanding the possibility, threat
or occurrence of a Change of Control (as defined in Section 1 hereof) of the
Company.  The Board believes it is
imperative to diminish the inevitable distraction of the Executive arising from
the personal uncertainties and risks created by a pending or threatened Change
of Control, to encourage the Executive’s full attention and dedication to the
Company currently and in the event of any threatened or pending Change of Control,
and to provide the Executive with reasonable compensation and benefit
arrangements upon a Change of Control.

 

In order to accomplish these objectives, the Board has
caused the Company to enter into this Agreement.

 

1.                                      Definitions

 

1.1                                 “Change of Control” shall have the definition set forth
in Appendix A hereto, which is hereby incorporated by reference.

 

1.2                                 “Change of Control Date” shall mean the first date on
which a Change of Control occurs.

 

1.3                                 “Employment Period” shall mean the two (2) year period
commencing on the Change of Control Date and ending on the second anniversary
of such date.

 

2.                                      Term

 

The initial term of this Agreement (“Initial Term”) shall
be for a period of one (1) year from the date of this Agreement as first
appearing above; provided, however, that this Agreement shall automatically
renew for successive additional one (1) year periods (“Renewal Terms”)
unless notice of nonrenewal is given by either party to the other at least
ninety (90) days prior to the end of the Initial Term or any Renewal Term, and
provided further that if a Change in Control occurs during the Term, the

 

 

Term shall automatically extend for the duration of the Employment
Period.  The “Term” of this Agreement shall be the Initial
Term plus all Renewal Terms and, if applicable, the duration of the Employment
Period.  At the end of the Term, this
Agreement shall terminate without further action by either the Company or the
Executive.

 

3.                                      Employment

 

3.1                               Employment
Period

 

During the Employment Period, the Company hereby
agrees to continue the Executive in its employ or in the employ of its
affiliated companies, and the Executive hereby agrees to remain in the employ
of the Company or its affiliated companies, in accordance with the terms and
provisions of this Agreement; provided, however, that either the Company or the
Executive may terminate the employment relationship subject to the terms of
this Agreement.

 

3.2                               Position and Duties

 

During the Employment Period, the Executive’s
position, authority, duties and responsibilities shall be at least commensurate
in all material respects with the most significant of those held, exercised and
assigned at any time during the ninety (90) day period immediately preceding
the Change of Control Date.

 

3.3                               Location

 

During the Employment Period, the Executive’s services
shall be performed at the Company’s headquarters on the Change of Control Date
or any office that is subsequently designated as the headquarters of the
Company and is less than thirty (30) miles from such location.

 

3.4                               Employment at Will

 

The Executive and the Company acknowledge that, except
as may otherwise be provided under any other written agreement between the
Executive and the Company, the employment of the Executive by the Company or
its affiliated companies is “at will” and may be terminated by either the
Executive or the Company or its affiliated companies at any time with or
without cause.  Moreover, if prior to
the Change of Control Date, the Executive’s employment with the Company or its
affiliated companies terminates for any reason, then the Executive shall have
no further rights under this Agreement; provided, however, that the Company may
not avoid liability for any termination payments that would have been required
during the Employment

 

2

 

Period pursuant to Section 8 hereof by terminating the Executive
prior to the Employment Period where such termination is carried out in
anticipation of a Change of Control and the principal motivating purpose is to
avoid liability for such termination payments.

 

4.                                      Attention And Effort

 

During the Employment Period, and excluding any
periods of vacation and sick leave to which the Executive is entitled, the
Executive will devote all of his productive time, ability, attention and effort
to the business and affairs of the Company and the discharge of the
responsibilities assigned to him hereunder, and will use his reasonable best
efforts to perform faithfully and efficiently such responsibilities.  It shall not be a violation of this
Agreement for the Executive to (a) serve on corporate, civic or charitable
boards or committees, (b) deliver lectures, fulfill speaking engagements
or teach at educational institutions, (c) manage personal investments, or
(d) engage in activities permitted by the policies of the Company or as
specifically permitted by the Company, so long as such activities do not
significantly interfere with the performance of the Executive’s
responsibilities in accordance with this Agreement.  It is expressly understood and agreed that to the extent any such
activities have been conducted by the Executive prior to the Employment Period,
the continued conduct of such activities (or the conduct of activities similar
in nature and scope thereto) during the Employment Period shall not thereafter
be deemed to interfere with the performance of the Executive’s responsibilities
to the Company.

 

5.                                      Compensation

 

As long as the Executive remains employed by the
Company during the Employment Period, the Company agrees to pay or cause to be
paid to the Executive, and the Executive agrees to accept in exchange for the
services rendered hereunder by him, the following compensation:

 

5.1                               Salary

 

The Executive shall receive an annual base salary (the
“Annual Base Salary”), at least equal to the annual
salary established by the Board or the Compensation Committee of the Board (the
“Compensation Committee”) or the Chief Executive Officer
for the fiscal year in which the Change of Control Date occurs.  The Annual Base Salary shall be paid in
substantially equal installments and at the same intervals as the salaries of
other executives of the Company are paid. 
The Board or the Compensation Committee or the Chief Executive Officer shall
review the Annual Base Salary at least annually and shall determine in good
faith and consistent with any generally applicable Company policy any increases
for future years.

 

3

 

5.2                               Bonus

 

In addition to the Annual Base Salary, the Executive shall
be awarded, for each fiscal year ending during the Employment Period, an annual
bonus (the “Annual Bonus”) in cash at
least equal to the average annualized (for any fiscal year consisting of less
than twelve (12) full months) bonus paid or payable (including by reason of any
deferral and including the value of any stock awards and the compensation
expense disclosed in the Company’s financial statements for the grant of any
stock options) to the Executive by the Company and its affiliated companies in
respect of the three fiscal years immediately preceding the fiscal year in
which the Change of Control Date occurs. 
Each Annual Bonus shall be paid no later than ninety (90) days after the
end of the fiscal year for which the Annual Bonus is awarded, unless the
Executive shall elect to defer the receipt of the Annual Bonus.

 

6.                                      Benefits

 

6.1                               Incentive, Retirement and Welfare Benefit Plans;
Vacation

 

During the Employment Period, the Executive shall be
entitled to participate, subject to and in accordance with applicable
eligibility requirements, in such fringe benefit programs as shall be generally
made available to other executives of the Company and its affiliated companies
from time to time during the Employment Period by action of the Board (or any
person or committee appointed by the Board to determine fringe benefit programs
and other emoluments), including, without limitation, paid vacations; any stock
purchase, savings or retirement plan, practice, policy or program; and all
welfare benefit plans, practices, policies or programs (including, without
limitation, medical, prescription, dental, disability, salary continuance,
employee life, group life, accidental death and travel accident insurance plans
or programs).

 

6.2                               Expenses

 

During the Employment Period, the Executive shall be
entitled to receive prompt reimbursement for all reasonable employment expenses
incurred by him in accordance with the policies, practices and procedures of
the Company and its affiliated companies in effect for the executives of the
Company and its affiliated companies during the Employment Period.

 

7.                                      Termination

 

During the Employment Period, employment of the
Executive may be terminated as follows, but, in any case, the nondisclosure
provisions set forth in

 

4

 

Section 10 hereof shall survive the termination of this Agreement
and the termination of the Executive’s employment with the Company:

 

7.1                               By the Company or the Executive

 

At any time during the Employment Period, the Company
may terminate the employment of the Executive with or without Cause (as defined
below), and the Executive may terminate his employment for Good Reason (as
defined below) or for any reason, upon giving the Notice of Termination (as
defined below).

 

7.2                               Automatic Termination

 

This Agreement and the Executive’s employment during
the Employment Period shall terminate automatically upon the death or Total
Disability of the Executive.  The term “Total Disability” as used herein shall mean the
Executive’s inability (with such accommodation as may be required by law and
which places no undue burden on the Company), as determined by a physician
selected by the Company and acceptable to the Executive, to perform the duties
set forth in Section 3.2 hereof for a period or periods aggregating twelve
(12) weeks in any three hundred sixty-five (365) day period as a result of
physical or mental illness, loss of legal capacity or any other cause beyond
the Executive’s control, unless the Executive is granted a leave of absence by
the Board.  The Executive and the
Company hereby acknowledge that the duties specified in Section 3.2 hereof
are essential to the Executive’s position and that Executive’s ability to
perform those duties is the essence of this Agreement.

 

7.3                               Notice of Termination

 

Any termination by the Company or by the Executive
during the Employment Period shall be communicated by the Notice of Termination
to the other party given in accordance with Section 12 hereof.  The term “Notice
of Termination” shall mean a written notice that
(a) indicates the specific termination provision in this Agreement relied
upon and (b) to the extent applicable, sets forth in reasonable detail the
facts and circumstances claimed to provide a basis for termination of the
Executive’s employment under the provision so indicated.  The failure by the Executive or the Company
to set forth in the Notice of Termination any fact or circumstance that
contributes to a showing of Good Reason or Cause shall not waive any right of
the Executive or the Company hereunder or preclude the Executive or the Company
from asserting such fact or circumstance in enforcing the Executive’s or the
Company’s rights hereunder.

 

5

 

7.4                               Date of Termination

 

During the Employment Period, “Date
of Termination” means (a) if the Executive’s employment is
terminated by reason of death, at the end of the calendar month in which the
Executive’s death occurs, (b) if the Executive’s employment is terminated
by reason of Total Disability, immediately upon a determination by the
Company of the Executive’s Total Disability, and (c) in all other cases,
ten (10) days after the date of personal delivery or mailing of the Notice of
Termination.  The Executive’s employment
and performance of services will continue during such ten (10) day period;
provided, however, that the Company may, upon notice to the Executive and
without reducing the Executive’s compensation during such period, excuse the
Executive from any or all of his duties during such period.

 

8.                                      Termination Payments

 

In the event of termination of the Executive’s
employment during the Employment Period, all compensation and benefits set
forth in this Agreement shall terminate except as specifically provided in this
Section 8.

 

8.1                               Termination by the Company Other Than for Cause or by
the Executive for Good Reason

 

If during the Employment Period the Company terminates
the Executive’s employment other than for Cause or the Executive terminates his
employment for Good Reason, the Executive shall be entitled to:

 

(a)                                  receive
payment of the following accrued obligations (the “Accrued
Obligations”):

 

(i)                                     the
Annual Base Salary through the Date of Termination to the extent not
theretofore paid;

 

(ii)                                  the
product of (x) the Annual Bonus payable with respect to the fiscal year in
which the Date of Termination occurs and (y) a fraction the numerator of which
is the number of days in the current fiscal year through the Date of
Termination, and the denominator of which is three hundred sixty-five (365);
and

 

(iii)                               any compensation
previously deferred by the Executive (together with accrued interest or
earnings thereon, if any) and any accrued vacation pay that would be payable
under the Company’s standard policy, in each case to the extent not theretofore
paid;

 

6

 

(b)                                 an
amount as severance pay equal to the Annual Base Salary for the fiscal year in
which the Date of Termination occurs, subject to payment and potential
reduction as set forth in Section 8.5 hereof;

 

(c)                                  for
one year after the Date of Termination or until the Executive qualifies for
comparable medical and dental insurance benefits from another employer,
whichever occurs first, the Company shall pay the Executive’s premiums for
health insurance benefit continuation for the Executive and his family members,
if applicable, which the Company provides to the Executive under the provisions
of the federal Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended (“COBRA”), to the extent that
the Company would have paid such premiums had the Executive remained employed
by the Company (such continued payment is hereinafter referred to as “COBRA Continuation”); and

 

(d)                                 immediate
vesting of all outstanding stock options previously granted to the Executive by
the Company.

 

8.2                               Termination for Cause or Other Than for Good Reason

 

If during the Employment Period the Executive’s
employment shall be terminated by the Company for Cause or by the Executive for
other than Good Reason, this Agreement shall terminate without further
obligation on the part of the Company to the Executive, other than the
Company’s obligation to pay the Executive (a) the Annual Base Salary
through the Date of Termination, (b)  the amount of any compensation previously
deferred by the Executive, and (c) any accrued vacation pay that would be
payable under the Company’s standard policy, in each case to the extent
theretofore unpaid.

 

8.3                               Expiration of Term

 

In the event the Executive’s employment is not terminated
prior to expiration of the Term, this Agreement shall terminate without further
obligation on the part of the Company to the Executive, other than the
Company’s obligation to pay the Executive the product of (a) the Annual
Bonus payable with respect to the fiscal year in which the Term expired and
(b) a fraction the numerator of which is the number of days in the current
fiscal year through the end of the Term and the denominator of which is three
hundred sixty-five (365).

 

8.4                               Termination Because of Death or Total Disability

 

If during the Employment Period the Executive’s
employment is terminated by reason of the Executive’s death or Total
Disability, this Agreement shall terminate

 

7

 

automatically without further obligation on the part of the Company to
the Executive or his legal representatives under this Agreement, other than the
Company’s obligation to pay the Executive the Accrued Obligations (which shall
be paid to the Executive’s estate or beneficiary, as applicable in the case of
the Executive’s death), and to provide COBRA Continuation.

 

8.5                               Payment Schedule and Offset for Other Earnings

 

All payments of Accrued Obligations, or any portion
thereof payable pursuant to this Section 8, shall be made to the Executive
within ten (10) working days of the Date of Termination.  Any payments payable to the Executive
pursuant to Section 8.1(b) hereof shall be made to the Executive in the
form of salary continuation, payable at normal payroll intervals during the one
(1) year severance period, and subject to offset for other earnings of the
Executive in respect of the one (1) year severance period as follows:

 

(a)                                  The
Executive shall have no affirmative duty to seek other employment or otherwise
mitigate lost earnings during the one (1) year severance period.

 

(b)                                 The
Executive shall disclose to the Company any earnings received (or that the
Executive had the right to receive) from employment, consulting or performance
of other personal services during the one (1) year severance period, and the
source(s) of such earnings.

 

(c)                                  The
Company, in each payroll period that a severance payment is due, shall have the
right to offset on a dollar-for-dollar basis all such earnings that the
Executive received or had the right to receive during that payroll period.

 

(d)                                 In
the event the Company disputes whether Good Reason existed for the Executive to
terminate his employment for Good Reason, the Company shall pay salary
continuation as provided above in this Section 8.5 until the earliest of
(i) settlement by the parties, (ii) determination by arbitration in
accordance with Section 17 hereof that Good Reason did not exist, and
(iii) completion of the payments required by this Section 8.5 and
Section 8.1(b) hereof.  If, pursuant
to Section 17 hereof, an arbitrator determines that Good Reason did not
exist, the arbitrator shall also decide whether the Executive had a reasonable,
good-faith basis for claiming that there was Good Reason to terminate.  If the arbitrator determines that there was
not such a basis, the Executive shall be obligated to repay promptly to the
Company the salary continuation payments; if the arbitrator determines that
there was such a basis, the Executive shall not be obligated to repay the
salary continuation.

 

8

 

8.6                               Cause

 

For purposes of this Agreement, “Cause”
means cause given by the Executive to the Company and shall include, without
limitation, the occurrence of one (1) or more of the following events:

 

(a)                                  a
clear refusal to carry out any material lawful duties of the Executive or any
directions of the Board or senior management of the Company, all reasonably
consistent with the duties described in Section 3.2 hereof;

 

(b)                                 persistent
failure to carry out any lawful duties of the Executive described in Section
3.2 hereof or any directions of the Board or senior management reasonably
consistent with the duties herein set forth to be performed by the Executive,
provided, however, that the Executive has been given reasonable notice and
opportunity to correct any such failure;

 

(c)                                  violation
by the Executive of a state or federal criminal law involving the commission of
a crime against the Company or any other criminal act involving moral
turpitude;

 

(d)                                 current
abuse by the Executive of alcohol or controlled substances; deception, fraud,
misrepresentation or dishonesty by the Executive; or any incident materially
compromising the Executive’s reputation or ability to represent the Company
with investors, customers or the public; or

 

(e)                                  any
other material violation of any provision of this Agreement by the Executive,
subject to the notice and opportunity-to-cure requirements of Section 11
hereof.

 

8.7                               Good Reason

 

For purposes of this Agreement, “Good
Reason” means

 

(a)                                  the
assignment to the Executive of any duties materially inconsistent with the
Executive’s position, authority, duties or responsibilities as contemplated by
Section 3.2 hereof or any other action by the Company that results in a
material diminution in such position, authority, duties or responsibilities,
excluding for this purpose an isolated and inadvertent action not taken in bad
faith and that is remedied by the Company promptly after receipt of notice
thereof given by the Executive;

 

(b)                                 any
failure by the Company to comply with any of the provisions of Section 5
or Section 6 hereof, other than an isolated and inadvertent failure not
taken

 

9

 

in bad faith and that is remedied by the Company promptly after receipt
of notice thereof given by the Executive;

 

(c)                                  the
Company’s requiring the Executive to be based at any office or location other
than that described in Section 3.3 hereof;

 

(d)                                 any
failure by the Company to comply with and satisfy Section 13 hereof;
provided, however, that the Company’s successor has received at least ten (10)
days’ prior written notice from the Company or the Executive of the
requirements of Section 13 hereof; or

 

(e)                                  any
other material violation of any provision of this Agreement by the Company,
subject to the notice and opportunity-to-cure requirements of Section 11
hereof.

 

8.8                               Excess Parachute Limitation

 

If any portion of the payments or benefits for the
Executive under this Agreement or any other agreement or benefit plan of the
Company (including stock option plan) would be characterized as an “excess
parachute payment” to the Executive under Section 280G of the Internal
Revenue Code of 1986, as amended (the “Code”), the
Executive shall be paid any excise tax that the Executive owes under
Section 4999 of the Code as a result of such characterization, such excise
tax to be paid to the Executive at least ten (10) days prior to the date that
he is obligated to make the excise tax payment.  The determination of whether and to what extent any payments or
benefits would be “excess parachute payments” and the date by which any excise
tax shall be due, shall be determined in writing by recognized tax counsel
selected by the Company and reasonably acceptable to the Executive.

 

9.                                      Representations, Warranties and Other Conditions

 

In order to induce the Company to enter into this
Agreement, the Executive represents and warrants to the Company as follows:

 

9.1                               Health

 

The Executive is in good health and knows of no
physical or mental disability that, with any accommodation that may be required
by law and that places no undue burden on the Company, would prevent him from
fulfilling his obligations hereunder. 
The Executive agrees, if the Company requests, to submit to reasonable
periodic medical examinations by a physician or physicians designated by, paid
for and

 

10

 

arranged by the Company.  The
Executive agrees that the examination’s medical report shall be provided to the
Company.

 

9.2                               No Violation of Other Agreements

 

The Executive represents that neither the execution
nor the performance of this Agreement by the Executive will violate or conflict
in any way with any other agreement by which the Executive may be bound.

 

10.                               Nondisclosure; Return of Materials

 

10.1                        Nondisclosure

 

Except as required by his employment with the Company,
the Executive will not, at any time during the term of employment by the
Company, or at any time thereafter, directly, indirectly or otherwise, use,
communicate, disclose, disseminate, lecture upon or publish articles relating
to any confidential, proprietary or trade secret information without the prior
written consent of the Company.  The
Executive understands that the Company will be relying on this Agreement in
continuing the Executive’s employment, paying him compensation, granting him
any promotions or raises, or entrusting him with any information that helps the
Company compete with others.

 

10.2                        Return of Materials

 

All documents, records, notebooks, notes, memoranda,
drawings or other documents made or compiled by the Executive at any time, or
in his possession, including any and all copies thereof, shall be the property
of the Company and shall be held by the Executive in trust and solely for the
benefit of the Company, and shall be delivered to the Company by the Executive
upon termination of employment or at any other time upon request by the
Company.

 

11.                               Notice and Cure of Breach

 

Whenever a breach of this Agreement by either party is
relied upon as justification for any action taken by the other party pursuant
to any provision of this Agreement, other than clause (a), (b), (c) or (d)
of Section 8.6 hereof, before such action is taken, the party asserting
the breach of this Agreement shall give the other party at least twenty (20)
days’ prior written notice of the existence and the nature of such breach
before taking further action hereunder and shall give the party purportedly in
breach of this Agreement the opportunity to correct such breach during the
twenty (20) day period.

 

11

 

12.                               Form of Notice

 

Every notice required by the terms of this Agreement
shall be given in writing by serving the same upon the party to whom it was
addressed personally or by registered or certified mail, return receipt
requested, at the address set forth below or at such other address as may
hereafter be designated by notice given in compliance with the terms hereof:

 

	
  If to the Executive:

  	
  133 Burns Avenue

  
	
   

  	
  Atherton, CA 94027

  
	
   

  	
  Attn:  Doug
  B. Given, M.D., Ph.D.

  
	
   

  	
   

  
	
  If to the Company:

  	
  NeoRx Corporation

  
	
   

  	
  410 West Harrison

  
	
   

  	
  Seattle, Washington  98119

  
	
   

  	
  Attn:  President

  
	
   

  	
   

  
	
  With a copy to:

  	
  Perkins Coie LLP

  
	
   

  	
  1201 Third Avenue, 40th Floor

  
	
   

  	
  Seattle, Washington 98101-3099

  
	
   

  	
  Attn:  James R. Lisbakken

  

 

Except as set forth in Section 7.4 hereof, if
notice is mailed, such notice shall be effective upon mailing.

 

13.                               Assignment

 

This Agreement is personal to the Executive and shall
not be assignable by the Executive.

 

The Company shall assign to and require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise)
to all or substantially all the business and/or assets of the Company to assume
expressly and agree to perform this Agreement in the same manner and to the
same extent that the Company would be required to perform it if no such
succession had taken place.  As used in
this Agreement, “Company” shall mean NeoRx
Corporation and any successor to its business and/or assets as aforesaid that
assumes and agrees to perform this Agreement by operation of law, or
otherwise.  All the terms and provisions
of this Agreement shall be binding upon and inure to the benefit of and be
enforceable by the parties hereto and their respective successors and permitted
assigns.

 

12

 

14.                               Waivers

 

No delay or failure by any party hereto in exercising,
protecting or enforcing any of its rights, titles, interests or remedies
hereunder, and no course of dealing or performance with respect thereto, shall
constitute a waiver thereof.  The
express waiver by a party hereto of any right, title, interest or remedy in a
particular instance or circumstance shall not constitute a waiver thereof in
any other instance or circumstance.  All
rights and remedies shall be cumulative and not exclusive of any other rights
or remedies.

 

15.                               Amendments In Writing

 

No amendment, modification, waiver, termination or
discharge of any provision of this Agreement, or consent to any departure
therefrom by either party hereto, shall in any event be effective unless the
same shall be in writing, specifically identifying this Agreement and the
provision intended to be amended, modified, waived, terminated or discharged
and signed by the Company and the Executive, and each such amendment,
modification, waiver, termination or discharge shall be effective only in the
specific instance and for the specific purpose for which given.  No provision of this Agreement shall be
varied, contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by the Company and the Executive.

 

16.                               Applicable Law

 

This Agreement shall in all respects, including all
matters of construction, validity and performance, be governed by, and
construed and enforced in accordance with, the laws of the State of Washington,
without regard to any rules governing conflicts of laws.

 

17.                               Arbitration; Attorneys’ Fees

 

Except in connection with enforcing Section 10
hereof, for which legal and equitable remedies may be sought in a court of law,
any dispute arising under this Agreement shall be subject to arbitration.  The arbitration proceeding shall be conducted
in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (the “AAA Rules”) then in effect,
conducted by one arbitrator either mutually agreed upon or selected in
accordance with the AAA Rules.  The
arbitration shall be conducted in King County, Washington, under the
jurisdiction of the Seattle office of the American Arbitration
Association.  The arbitrator shall have
authority only to interpret and apply the provisions of this Agreement, and
shall have no authority to add to, subtract from or otherwise modify the terms
of this Agreement.

 

13

 

Any demand for arbitration must be made within sixty (60) days of the
event(s) giving rise to the claim that this Agreement has been breached.  The arbitrator’s decision shall be final and
binding, and each party agrees to be bound to by the arbitrator’s award,
subject only to an appeal therefrom in accordance with the laws of the State of
Washington.  Either party may obtain
judgment upon the arbitrator’s award in the Superior Court of King, County,
Washington.

 

If it becomes necessary to pursue or defend any legal
proceeding, whether in arbitration or court, in order to resolve a dispute
arising under this Agreement, the prevailing party in any such proceeding shall
be entitled to recover its reasonable costs and attorneys’ fees.

 

18.                               Severability

 

If any provision of this Agreement shall be held
invalid, illegal or unenforceable in any jurisdiction, for any reason,
including, without limitation, the duration of such provision, its geographical
scope or the extent of the activities prohibited or required by it, then, to
the full extent permitted by law, (a) all other provisions hereof shall
remain in full force and effect in such jurisdiction and shall be liberally
construed in order to carry out the intent of the parties hereto as nearly as
may be possible, (b) such invalidity, illegality or unenforceability shall
not affect the validity, legality or enforceability of any other provision
hereof, and (c) any court or arbitrator having jurisdiction thereover
shall have the power to reform such provision to the extent necessary for such
provision to be enforceable under applicable law.

 

19.                               Entire Agreement

 

This Agreement constitutes the entire agreement
between the Company and the Executive with respect to the subject matter
hereof, and all prior or contemporaneous oral or written communications,
understandings or agreements between the Company and the Executive with respect
to such subject matter are hereby superseded and nullified in their entireties,
except that the Proprietary Information and Invention Agreement between the
Company and the Executive shall continue in full force and effect to the extent
not superseded by Section 10 hereof.

 

20.                               Withholding

 

The Company may withhold from any amounts payable
under this Agreement such federal, state or local taxes as shall be required to
be withheld pursuant to any applicable law or regulation.

 

14

 

21.                               Counterparts

 

This Agreement may be executed in counterparts, each
of which counterparts shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties have executed and
entered into this Agreement effective on the date first set forth above.

 

	
   

  	
  NEORX
  CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  LINDA T. FINDLAY

  
	
   

  	
   

  	
  Name:

  	
  Linda
  T. Findlay

  
	
   

  	
   

  	
  Its:

  	
  Vice
  President, Human Resources

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  EXECUTIVE

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  DOUGLASS B. GIVEN

  
	
   

  	
   

  	
  Name:
  Douglass B. Given, M.D., Ph.D.

  
					

 

15

 

APPENDIX A

 

For purposes of this Agreement, a “Change
of Control” shall mean:

 

(a)                                  A
“Board Change” that, for purposes of this Agreement,
shall have occurred if a majority (excluding vacant seats) of the seats on the
Board are occupied by individuals who were neither (i) nominated by a
majority of the Incumbent Directors nor (ii) appointed by directors so
nominated.  An “Incumbent
Director” is a member of the Board who has been either
(i) nominated by a majority of the directors of the Company then in office
or (ii) appointed by directors so nominated, but excluding, for this
purpose, any such individual whose initial assumption of office occurs as a
result of either an actual or threatened election contest (as such terms are
used in Rule 14a-11 of Regulation 14A promulgated under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)) or
other actual or threatened solicitation of proxies or consents by or on behalf
of a Person (as hereinafter defined) other than the Board; or

 

(b)                                 The
acquisition by any individual, entity or group (within the meaning of
Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”)
of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) of (i) twenty percent (20%) or more of either (A) the
then outstanding shares of Common Stock of the Company (the “Outstanding
Company Common Stock”) or (B) the combined voting power of
the then outstanding voting securities of the Company entitled to vote
generally in the election of directors (the “Outstanding
Company Voting Securities”), in the case of either (A) or
(B) of this clause (i), which acquisition is not approved in advance by a
majority of the Incumbent Directors, or (ii) thirty-three percent (33%) or
more of either (A) the Outstanding Company Common Stock or (B) the
Outstanding Company Voting Securities, in the case of either (A) or (B) of
this clause (ii), which acquisition is approved in advance by a majority of the
Incumbent Directors; provided, however, that the following acquisitions shall
not constitute a Change of Control: 
(x) any acquisition by the Company, (y) any acquisition by any
employee benefit plan (or related trust) sponsored or maintained by the Company
or any corporation controlled by the Company, or (z) any acquisition by
any corporation pursuant to a reorganization, merger or consolidation, if,
following such reorganization, merger or consolidation, the conditions
described in clauses (i), (ii) and (iii) of subsection (c) of this
Appendix A are satisfied; or

 

16

 

(c)                                  Approval
by the shareholders of the Company of a reorganization, merger or
consolidation, in each case, unless, immediately following such reorganization,
merger or consolidation, (i) more than sixty percent (60%) of,
respectively, the then outstanding shares of common stock of the corporation
resulting from such reorganization, merger or consolidation and the combined
voting power of the then outstanding voting securities of such corporation
entitled to vote generally in the election of directors is then beneficially
owned, directly or indirectly, by all or substantially all the individuals and
entities who were the beneficial owners, respectively, of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities immediately
prior to such reorganization, merger or consolidation in substantially the same
proportion as their ownership immediately prior to such reorganization, merger
or consolidation of the Outstanding Company Common Stock and the Outstanding
Company Voting Securities, as the case may be, (ii) no Person (excluding
the Company, any employee benefit plan (or related trust) of the Company or
such corporation resulting from such reorganization, merger or consolidation
and any Person beneficially owning, immediately prior to such reorganization,
merger or consolidation, directly or indirectly, thirty-three percent (33%) or
more of the Outstanding Company Common Stock or the Outstanding Company Voting
Securities, as the case may be) beneficially owns, directly or indirectly,
thirty-three percent (33%) or more of, respectively, the then outstanding
shares of common stock of the corporation resulting from such reorganization,
merger or consolidation or the combined voting power of the then outstanding
voting securities of such corporation entitled to vote generally in the
election of directors, and (iii) at least a majority of the members of the
board of directors of the corporation resulting from such reorganization,
merger or consolidation were the Incumbent Directors at the time of the
execution of the initial agreement providing for such reorganization, merger or
consolidation; or

 

(d)                                 Approval
by the shareholders of the Company of (i) a complete liquidation or
dissolution of the Company or (ii) the sale or other disposition of all or
substantially all the assets of the Company, other than to a corporation with
respect to which immediately following such sale or other disposition, (A) more
than sixty percent (60%) of, respectively, the then outstanding shares of
common stock of such corporation and the combined voting power of the then
outstanding voting securities of such corporation entitled to vote generally in
the election of directors is then beneficially owned, directly or indirectly,
by all or substantially all the individuals and entities who were the
beneficial owners, respectively, of the Outstanding Company Common Stock and
the Outstanding Company Voting Securities immediately prior to such sale or
other disposition in substantially the same proportion as their ownership,
immediately prior to such sale or other disposition, of the Outstanding Company

 

17

 

Common Stock and the Outstanding Company Voting Securities, as the case
may be, (B) no Person (excluding the Company, any employee benefit plan
(or related trust) of the Company or such corporation and any Person
beneficially owning, immediately prior to such sale or other disposition, directly
or indirectly, thirty-three percent (33%) or more of the Outstanding Company
Common Stock or the Outstanding Company Voting Securities, as the case may be)
beneficially owns, directly or indirectly, thirty-three percent (33%) or
more of, respectively, the then outstanding shares of common stock of such
corporation and the combined voting power of the then outstanding voting
securities of such corporation entitled to vote generally in the election of
directors, and (C) at least a majority of the members of the board of
directors of such corporation were approved by a majority of the Incumbent
Directors at the time of the execution of the initial agreement or action of
the Board providing for such sale or other disposition of the Company’s assets.

 

18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]